Alimta-Related Skin Reactions with and Without Oral Steroids
This study supports the use of intravenous dexamethasone 10 mg before pemetrexed infusion in place of three days of oral dexamethasone 4 mg twice daily at UNMCCC,” the authors wrote. The post Alimta-Related Skin Reactions with and Without Oral Steroids appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - November 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

UK Study Matches Mesothelioma Treatments to Genetic Profile
University of Leicester researchers soon will open the first molecularly stratified clinical trial for malignant mesothelioma with the hope of moving the future of treatment toward more personalization. The phase II trial in the United Kingdom is designed to match therapy with a patient’s specific genetic profile. “We’re trying to bring the right drug to the right patient at the right time,” Professor Dean Fennell, chair of thoracic medical oncology at Leicester and chief trial investigator, told Asbestos.com. “We need to find different treatments that work for different people. This is a step...
Source: Asbestos and Mesothelioma News - October 12, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Review Highlights Better Targets for Mesothelioma Therapy
A review on targeted therapies for malignant pleural mesothelioma (MPM) provides fresh insight into why this cancer is so difficult to treat and ideas for improving outcomes. “Despite more than two decades of intensive research on the possible treatments for MPM, the results have so far been disappointing,” the authors wrote. According to the in-depth review, published in Critical Reviews in Hematology/Oncology, the next steps toward more tailored mesothelioma treatment will come from learning more about the changes driving abnormal cell communication. Researchers will use this information to personalize treatm...
Source: Asbestos and Mesothelioma News - October 4, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2018 Category: Pharmaceuticals Source Type: news

Novel Mesothelioma Treatment Closer to FDA Approval
Standard-of-care treatment for patients with pleural mesothelioma may soon include Tumor Treating Fields (TTF), a novel therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth. In the wake of recently released results from Novocure’s STELLAR phase II clinical trial, the U.S. Food and Drug Administration (FDA) is expected to approve the treatment within the next six months, giving mesothelioma patients another much-needed option. “At this point, it should be a relatively rapid approval process,” Dr. Eilon Kirson, chief science officer at Novocure, the oncology company...
Source: Asbestos and Mesothelioma News - September 17, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

EC Approves Frontline Lung Cancer Combo EC Approves Frontline Lung Cancer Combo
The European Commission (EC) has approved the combination of pembrolizumab, pemetrexed, and platinum chemotherapy for the first-line treatment of metastatic non – small cell lung cancer.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Novocure touts combined TTF, chemotherapy mesothelioma study data
Novocure (NSDQ:NVCR) today released results from the Stellar phase 2 registration trial exploring the use of its Tumor Treating Fields and standard of care chemotherapy to chemotherapy alone in treating mesothelioma, touting a significant extension in median overall survival. Patients with malignant pleural mesothelioma who received TTF treatment alongside pemetrexed and cisplatin or carboplatin experienced a median overall survival of 18.2 months, compared to 12.1 months in a historical control, the St. Helier, Jersey-based company said. Read the whole story on our sister site, Drug Delivery Business News The post No...
Source: Mass Device - September 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Drug-Device Combinations Oncology NovoCure Source Type: news

Mesothelioma Case Report Touts Success with Opdivo
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving. Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer. A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce. “We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the Universit...
Source: Asbestos and Mesothelioma News - July 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Roche today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death (PFS) compared to chemotherapy alone in the initial (first-line) treatment of advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - July 19, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Roche today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death (PFS) compared to chemotherapy alone in the initial (first-line) treatment of advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - July 19, 2018 Category: Pharmaceuticals Source Type: news

Dr Reddy's loses patent case with Eli Lilly over Alimta
The U.S. District Court for the Southern District of Indiana ruled in favor of Lilly, a release from the US drug maker said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 24, 2018 Category: Pharmaceuticals Source Type: news

U.S. District Court rules in favor of Lilly's Alimta patent
(Reuters) - Eli Lilly and Co said on Friday a U.S. District Court ruled in favor of its patent on Alimta vitamin regimen and prevented Hospira Inc and India's Dr. Reddy's Laboratories from launching generics until the patent expires. (Source: Reuters: Health)
Source: Reuters: Health - June 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma. The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma. “We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer T...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

‘Right to Try Act’ Could Aid Mesothelioma Patients
Patients with mesothelioma may soon find an easier path to experimental drugs and treatments after President Donald Trump signed the “Right to Try Act” into law last week. The new legislation will give terminally ill patients a more direct and quicker line to drugs still awaiting approval from the U.S. Food and Drug Administration (FDA), bypassing the often-cumbersome application process. The law also will protect doctors and pharmaceutical companies from the legal risks of allowing unapproved treatments. The bill was passed by the Senate in August 2017 and cleared the House of Representatives late last month....
Source: Asbestos and Mesothelioma News - June 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
New approval based on KEYNOTE-021, Cohort G1, results INDIANAPOLIS, June 5, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a ... Biopharmaceuticals, Oncology, FDA Eli Lilly, ALIMTA, pemetrexed, KEYTRUDA, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 5, 2018 Category: Pharmaceuticals Source Type: news

Pembrolizumab, Pemetrexed, and Carboplatin Improve Lung Cancer Survival
Bryant FurlowJun 3, 2018Adding pembrolizumab to pemetrexed and carboplatin for advanced nonsquamous NSCLC is associated with improved overall survival at 24 months. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Could Mesothelioma Chemotherapy Ever Be Obsolete?
Oncologist Dr. Arek Dudek at Regions Hospital Cancer Care Center in St. Paul, Minnesota, believes his clinical trial involving a novel immunotherapy combination could change the way doctors treat pleural mesothelioma. Dudek is opening the only Phase II trial evaluating the combination of nivalumab (Opdivo) and ramucirumab (Cyramza) for previously treated mesothelioma patients. “This strategy – if successful, like we think it will be – could make treatment with chemotherapy obsolete,” Dudek told Asbestos.com. “People can be really excited about this one.” He based his optimism on the pote...
Source: Asbestos and Mesothelioma News - June 1, 2018 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Novel Mesothelioma Treatment Uses Electrical Fields
Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer. Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients. The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - May 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

ONCOS-102 Mesothelioma Trial Moves Forward
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine. Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in. The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease. ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells. It is being developed by Targovax, a Scandina...
Source: Asbestos and Mesothelioma News - May 17, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
This research article has led to a Practice Update in DynaMed Plus. It concludes that addition of pembrolizumab to chemotherapy with pemetrexed and platinum-based drug increases overall survival in patients with previously untreated metastatic nonsquamous non-small cell lung cancer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 9, 2018 Category: Consumer Health News Source Type: news

New Clinical Trial Focuses on Immunotoxins and Mesothelioma
An exciting new mesothelioma clinical trial will study one approach for improving how well immunotoxin drugs work. The phase I trial is enrolling peritoneal and pleural mesothelioma patients. Immunotoxins, which are targeted therapies, attach to and destroy cancer cells. This approach already has shown promise in a small clinical trial. This new clinical trial will give mesothelioma patients an immunotoxin in combination with another substance to suppress the immune system. The goal of the National Cancer Institute (NCI) clinical trial is to learn how safe and tolerable the combination of the immunotoxin and immune suppre...
Source: Asbestos and Mesothelioma News - February 26, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Only U.S. Cryotherapy Trial for Mesothelioma Finds Success
Thoracic surgeon Dr. Shanda Blackmon at the Mayo Clinic in Rochester, Minnesota, believes there is a place for cryotherapy in the future multidisciplinary treatment of pleural mesothelioma. She wants to show it with this groundbreaking clinical trial. “We think [cryotherapy] could play an important role in treatment,” Blackmon told Asbestos.com. “So far, things look promising, but you can’t say anything specific without more numbers. Right now, it’s a little like telling a story.” Cryotherapy involves destroying cancer cells, or any abnormal tissues, by freezing them with controlled nitr...
Source: Asbestos and Mesothelioma News - February 14, 2018 Category: Environmental Health Authors: Daniel King Tags: ADI-PEG 20 cryoablation cryotherapy intrapleural measles virus Mayo Clinic mesothelioma clinical trial Opdivo pacific mesothelioma center pleural mesothelioma pleuroscopy Shanda Blackmon Surgery for Mesothelioma After Radiation Thera Source Type: news

Study: Preoperative Chemotherapy Useful for Mesothelioma
Oncologists in France are exploring the use of bidirectional chemotherapy as a pre-operative tool for peritoneal mesothelioma, increasing the eligibility of patients for aggressive surgery. Their bidirectional chemotherapy — which typically includes a pemetrexed (Alimta) and cisplatin combination — is delivered directly into the abdominal cavity to reduce tumor burden and make cytoreductive surgery more manageable. Doctors at Gustave Roussy, one of Europe’s premier cancer centers, documented this novel use in a study published in the November issue of Annals of Surgical Oncology. “This is the first ...
Source: Asbestos and Mesothelioma News - December 13, 2017 Category: Environmental Health Authors: Daniel King Tags: bidirectional chemotherapy cytoreductive surgery Gustave Roussy hyperthermic intraperitoneal chemotherapy Paul Sugarbaker peritoneal mesothelioma Washington Cancer Institute Source Type: news

French Oncologists Upgrade Mesothelioma Standard of Care
Oncologists throughout France have joined the U.S.-based National Comprehensive Cancer Network (NCCN) in upgrading their recommended standard-of-care treatment regimen for unresectable pleural mesothelioma. Both groups have added bevacizumab (Avastin) to the traditional cisplatin and pemetrexed chemotherapy combination, expecting to see longer patient survival. “This is a major advancement for the care of mesothelioma patients,” Dr. Gerard Zalcman, head of thoracic oncology at Bichat-Claude Bernard Hospital, told Asbestos.com. “Clearly, this drug can change the natural history of this tumor.” Bevaci...
Source: Asbestos and Mesothelioma News - November 20, 2017 Category: Environmental Health Authors: Daniel King Tags: American Society of Clinical Oncology Avastin bevacizumab Bichat-Claude Bernard Hospital French Cooperative Thoracic Intergroup Gerard Zalcman National Comprehensive Cancer Network nintedanib Ofev pleural mesothelioma chemotherapy Source Type: news

Eagle Pharma Gets Tentative FDA Approval for Lilly's Alimta Version Eagle Pharma Gets Tentative FDA Approval for Lilly's Alimta Version
Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 30, 2017 Category: Consumer Health News Tags: Pharmacist News Source Type: news

Eagle Pharma gets tentative FDA approval for Lilly's Alimta version
(Reuters) - Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta. (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Eli Lilly defeats challenge to Alimta cancer drug patent
(Reuters) - A federal patent review board on Thursday rejected a challenge to a patent covering Eli Lilly and Co's Alimta drug to treat some lung cancers and mesothelioma. (Source: Reuters: Health)
Source: Reuters: Health - October 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Promising Drug Reduces Growth of Aggressive Mesothelioma
Scientists in Italy have found a platinum-based drug that successfully lessens growth of the most aggressive type of mesothelioma cancer cells. Researchers at the University of Salento discovered the experimental drug Ptac2S was more effective in reducing the spread of sarcomatoid malignant pleural mesothelioma cells in mice compared to cisplatin — the most widely used chemotherapy drug for treating mesothelioma. Sarcomatoid is the least common of the three mesothelioma cell types but is considered more aggressive and harder to treat. A diagnosis with the sarcomatoid cell type is typically associated with a poor pro...
Source: Asbestos and Mesothelioma News - August 7, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Alimta alternatives to cisplatin Antonella Muscella Biphasic mesothelioma chemotherapy for mesothelioma chemotherapy resistance DNA adducts epithelioid mesothelioma genomic activities mesothelioma clinical trials mesothelioma survival Source Type: news

Not Legit? The Superiority of Pemetrexed in Lung Cancer Not Legit? The Superiority of Pemetrexed in Lung Cancer
Pemetrexed's reputation for superior efficacy in the initial treatment of lung cancer is based on less-than-definitive data but has resulted in high usage and sales.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Bone Health Drug Inhibits Mesothelioma Tumor Growth
A drug used to treat bone disease and high blood calcium levels may carry benefits as part of a combination treatment for malignant pleural mesothelioma, a recent study concluded. Researchers at the University of Alabama at Birmingham Comprehensive Cancer Center conducted a pilot study testing the effects of zoledronic acid — a bisphosphonate, or bone health drug, marketed as Reclast and Zometa — against a small group of patients with unresectable pleural mesothelioma. The study, published in the June edition of Lung Cancer: Targets and Therapy journal, was a follow-up to preclinical research showing zoledron...
Source: Asbestos and Mesothelioma News - July 20, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bone disease treatment keytruda mesothelioma treatments Muhammad Omer Jamil reclast treating malignant pleural mesothelioma University of Alabama at Birmingham Comprehensive Cancer Center Zoledronic acid zometa Source Type: news

UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents
INDIANAPOLIS, July 7, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that the UK Supreme Court has decided in the litigation relating to alternative salt forms of Alimta® (pemetrexed disodium) that ... Biopharmaceuticals, Litigation Eli Lilly, Actavis, Alimta, pemetrexed disodium (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 7, 2017 Category: Pharmaceuticals Source Type: news

UK Supreme Court rules in favor of Lilly's Alimta patents
(Reuters) - Eli Lilly and Co said on Friday the UK Supreme Court ruled that generic versions of the company's top-selling cancer drug Alimta sold by Actavis directly infringe certain Lilly patents in the UK, France, Italy and Spain. (Source: Reuters: Health)
Source: Reuters: Health - July 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Seattle Cancer Center Opens Latest Mesothelioma Clinical Trial
The Seattle Cancer Care Alliance has opened a phase II clinical trial involving durvalumab, the promising immunotherapy drug, in combination with chemotherapy for the first-line treatment of unresectable pleural mesothelioma. The U.S. Food and Drug Administration (FDA) already granted accelerated approval to durvalumab in May for the treatment of bladder cancer. Researchers have also lauded the drug for its effectiveness in earlier lung cancer clinical trials. “We have every reason to believe it will be effective with mesothelioma, too,” Dr. Bernardo Goulart, chief trial investigator and medical oncologist at t...
Source: Asbestos and Mesothelioma News - June 27, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: cancer in seattle doctor Bernardo Goulart mesothelioma clinical trials mesothelioma in seattle mesothelioma treatment seattle cancer care alliance Source Type: news

Nintedanib Combination Delayed Progression in Malignant Mesothelioma
Adding nintedanib to pemetrexed/cisplatin improved the progression-free survival of patients with malignant pleural mesothelioma compared with placebo. (Source: CancerNetwork)
Source: CancerNetwork - June 22, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Lung Cancer News Source Type: news

Mesothelioma Clinical Trial Opens with High Expectations
Newly diagnosed mesothelioma patients around the world have begun enrolling in a much-anticipated, phase III clinical trial involving an immunotherapy drug combination with groundbreaking potential. The trial, designed as first-line therapy for unresectable pleural mesothelioma, will measure the effectiveness of nivolumab (Opdivo) and ipilimumab (Yervoy) against standard-of-care chemotherapy. A presentation this month at the 2017 American Society of Clinical Oncology (ASCO) annual meeting sparked high expectations for the trial, detailing early, impressive effectiveness involving the two drugs in second-line and third-lin...
Source: Asbestos and Mesothelioma News - June 16, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center American Society of Clinical Oncology Bristol-Myers Squibb cancer immunotherapy research cisplatin for mesothelioma Cleveland Clinic Cancer Center CRS-207 disease control rate Dr. Arnaud Scherpereel Dr. Patrick Ma Source Type: news

Genetic Biomarkers Key to Future Mesothelioma Treatment
Researchers in Slovenia have developed a unique, treatment-recommendation model for mesothelioma patients based heavily upon individualized, genetic biomarkers. They believe their model will lead to better patient outcomes and significantly improve the response rate to chemotherapy, which is still less than 40 percent with mesothelioma. “This is just a start, but it’s going to be the way to go in the future, personalizing treatment,” Dr. Vita Dolzan, founder of Pharmacogenetics Laboratory at the University of Ljubljana’s Institute of Biochemistry, told Asbestos.com. “We’re excited about ...
Source: Asbestos and Mesothelioma News - May 22, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Anhovo Asbestos Valley Slovenia chemotherapy drugs for mesothelioma cisplatin CRP protein Dr. Vita Dolzan gemcitabine genetic biomarkers genetic makeup mesothelioma patients Genotyping mesothelioma treatment strategies pemetrexed p Source Type: news

Latest Keytruda Approval Promising for Mesothelioma Patients
The U.S. Food and Drug Administration (FDA) expanded its approval of pembrolizumab for first-line treatment of metastatic non-small cell lung cancer last week, moving it closer to becoming a viable treatment option for patients with pleural mesothelioma. Pembrolizumab is marketed by Merck & Co. under the brand name Keytruda. It helps the body’s immune system detect and destroy cancer cells. The FDA approved its first-line use in combination with pemetrexed and carboplatin, two chemotherapy agents used regularly for mesothelioma. Pembrolizumab, the most well-known immunotherapy drug, is being studied for use with...
Source: Asbestos and Mesothelioma News - May 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: carboplatin chemotherapy for mesothelioma Dr. Raymond Wong Dr. Tawee Tanvetyanon FDA approval Keytruda first line treatment for mesothelioma Hodgkin lymphoma jimmy carter keytruda clinical trial keytruda for mesothelioma melanoma Mer Source Type: news

FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression
Dateline City: KENILWORTH, N.J. First Approval for an Anti-PD-1 Therapy as a Combination in Metastatic Nonsquamous NSCLCKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in combination with pemetrexed (brand name Alimta®) and carboplatin (pem/carbo), a commonly used chemotherapy regimen, for the first-line treatment of metastatic nonsquamous NSCLC, irrespective of PD-L1 expression.Language: ...
Source: Merck.com - Product News - May 10, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news

Case Report Explores Benefits of Alimta as Second-Line Mesothelioma...
A Croatian man with advanced peritoneal mesothelioma lived for more than four years when treated with pemetrexed after relapse.(PRWeb May 09, 2017)Read the full story at http://www.prweb.com/releases/2017/05/prweb14316001.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 9, 2017 Category: Pharmaceuticals Source Type: news

New Mesothelioma Clinical Trial for Pleural, Peritoneal Patients
Pleural and peritoneal mesothelioma patients are eligible for a new clinical trial that combines the latest antibody-drug conjugate with standard-of-care chemotherapy at the Ochsner Medical Center in New Orleans. The drug, anetumab ravtansine (BAY 94-9343), is the highly touted conjugate that mixes immunotherapy with cytotoxic therapy and targets mesothelin, the tumor surface protein found in 85-90 percent of mesothelioma cancer patients. The Ochsner trial, which is currently recruiting participants, is the first time researchers will administer anetumab ravtansine in a first-line setting for mesothelioma. “It’...
Source: Asbestos and Mesothelioma News - April 28, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: anetumab ravtansine mesothelioma chemotherapy mesothelioma clinical trial new mesothelioma treatment ochsner clinical trial Source Type: news

Pemetrexed cost effective with assistance program in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 31, 2017 Category: Drugs & Pharmacology Source Type: news

Eli Lilly Beats Teva Appeal on Generic Cancer Drug
Eli Lilly blocks Teva from selling a generic equivalent of its lung cancer drug Alimta (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 13, 2017 Category: Pharmaceuticals Source Type: news

Sugarbaker Touts New Clinical Study for Mesothelioma Patients
This study expands on what we already know about surgery and chemotherapy for mesothelioma, and combines them in a new way…with the goal of reducing recurrence rates and improving survival and quality of life,” Groth said in a press release from the Baylor Medical Center. “The heated chemotherapy fluid is effective at killing cancer and making the chemotherapy work better.” Baylor also has other ongoing mesothelioma clinical trials: A phase II study of anetumab ravtansine for patients with unresectable pleural mesothelioma and high expression of mesothelin, a vulnerable, tumor-surface protein link...
Source: Asbestos and Mesothelioma News - December 22, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: baylor college of medicine chemotherapy for mesothelioma dr. david sugarbaker mesothelioma chemotherapy drugs mesothelioma clinical trial mesothelioma treatment center at baylor Source Type: news

Mesothelioma Trial for Nintedanib Shows Positive Results
Researchers have reported more promising results from an international, multicenter phase II clinical trial of the drug nintedanib, moving it another step closer to standard-of-care treatment for pleural mesothelioma. Nintedanib is a small-molecule enzyme inhibitor being studied as a way to increase the effectiveness of chemotherapy on mesothelioma and certain types of lung cancer. Researchers presented the results earlier this month at the World Conference on Lung Cancer in Vienna, Austria. The randomized clinical trial treated mesothelioma patients with a placebo and chemotherapy (pemetrexed/cisplatin) or nintedanib and ...
Source: Asbestos and Mesothelioma News - December 22, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: chemotherapy clinical trial chemotherapy for mesothelioma extending mesothelioma survival mesothelioma treatment nintedanib Source Type: news

Study Shows Impact of Chemotherapy on Mesothelioma
A U.S.-based study confirms what oncology experts have suggested for years — chemotherapy treatment prolongs life expectancy for malignant mesothelioma patients. Wayne State University School of Medicine researchers linked data from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database with Medicare claims data. The study took into account patient characteristics such as age, gender and amount of asbestos exposure. Not only did the findings show mesothelioma patients who have chemotherapy live longer, but it also proved multimodal therapy increases survival even more. The s...
Source: Asbestos and Mesothelioma News - December 19, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: chemotherapy clinical trial chemotherapy for mesothelioma doctor shirish gadgeel first line treatment for mesothelioma Human Investigation Committee at Wayne State mesothelioma diagnosis peritoneal mesothelioma wayne state university Source Type: news

Predictors of Chemotherapy Efficacy in NSCLC Predictors of Chemotherapy Efficacy in NSCLC
Can biomarkers predict the efficacy of conventional chemotherapy, such as gemcitabine and pemetrexed, for treatment of NSCLC?Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Adding Pemetrexed to Gefitinib Improves PFS in EGFR-Mutated NSCLC
The combination of pemetrexed and gefitinib offered improved progression-free survival in East Asian patients with advanced nonsquamous NSCLC and activating EGFR mutations. (Source: CancerNetwork)
Source: CancerNetwork - August 8, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

New Mesothelioma Treatment Guidelines May Extend Survival
The National Comprehensive Cancer Network (NCCN) has changed its first-line treatment recommendation for unresectable pleural mesothelioma, believing it will extend patient survival significantly. The NCCN advisory panel recently added the monoclonal antibody bevacizumab to the long-standing chemotherapy combination of pemetrexed and cisplatin. Bevacizumab, also known by brand name Avastin, inhibits the formation of new blood vessels in tumors, effectively slowing the growth of cancer cells. It has successfully treated some types of lung and colorectal cancers. The NCCN recommendation is expected to be a precursor to the U...
Source: Asbestos and Mesothelioma News - July 26, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer chemotherapy chemotherapy drugs chemotherapy drugs for mesothelioma chemotherapy for mesothelioma mesothelioma treatment moffitt cancer center new chemotherapy drug Source Type: news